Yu S - Search Results

1

Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer.

Hu T, Yao Y, Yu S, Guo H, Han L, Wang W, Tian T, Hao Y, Liu Z, Nan K, Wang S. Hu T, et al. Among authors: yu s. J Biomed Res. 2013 Jul;27(4):283-90. doi: 10.7555/JBR.27.20130069. Epub 2013 Jul 6. J Biomed Res. 2013. PMID: 23885267 Free PMC article.

2

Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.

Hu T, Guo H, Wang W, Yu S, Han L, Jiang L, Ma J, Yang C, Guo Q, Nan K. Hu T, et al. Among authors: yu s. Oncol Rep. 2013 Oct;30(4):1707-14. doi: 10.3892/or.2013.2608. Epub 2013 Jul 9. Oncol Rep. 2013. PMID: 23842948

3

[CXCR4 and Nrf2 expressions in non-small cell lung cancer and their clinical implications].

Hu T, Yao Y, Yu S, Guo H, Tian T, Han L, Wang W, Guo Q, Wang J, Nan K, Wang S. Hu T, et al. Among authors: yu s. Nan Fang Yi Ke Da Xue Xue Bao. 2014 Feb;34(2):153-8. Nan Fang Yi Ke Da Xue Xue Bao. 2014. PMID: 24589587 Chinese.

4

SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway.

Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H, Tian T, Ruan ZP, Kang XM, Wang J, Wang SH, Nan KJ. Hu TH, et al. Among authors: yu s. Cancer Lett. 2014 Nov 28;354(2):417-26. doi: 10.1016/j.canlet.2014.08.012. Epub 2014 Aug 20. Cancer Lett. 2014. PMID: 25150783

5

Nrf2 promotes progression of non-small cell lung cancer through activating autophagy.

Wang J, Liu Z, Hu T, Han L, Yu S, Yao Y, Ruan Z, Tian T, Huang T, Wang M, Jing L, Nan K, Liang X. Wang J, et al. Among authors: yu s. Cell Cycle. 2017 Jun 3;16(11):1053-1062. doi: 10.1080/15384101.2017.1312224. Epub 2017 Apr 12. Cell Cycle. 2017. PMID: 28402166 Free PMC article.

6

Combined Evaluation of Expression of CXCR4 and Nrf2 as Prognostic Factor for Patients with Gastric Carcinoma.

Yu S, Wu T, Wang J, Cheng C, Wang J, Sun L, Liu C, Cao G, Hu T. Yu S, et al. Anticancer Agents Med Chem. 2018;18(3):388-393. doi: 10.2174/1871520617666171103112019. Anticancer Agents Med Chem. 2018. PMID: 29110625

7

MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP.

Yu S, Jing L, Yin XR, Wang MC, Chen YM, Guo Y, Nan KJ, Han LL. Yu S, et al. Oncotarget. 2017 Sep 15;8(59):99757-99771. doi: 10.18632/oncotarget.20909. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245938 Free PMC article.

8

Loss of Beclin1 Expression and Nrf2 Overexpression are Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer.

Yu S, Cheng C, Wang J, Wang J, Qu Z, Ren H, Li Y, Ning Q, Chen M, Hu T. Yu S, et al. Anticancer Agents Med Chem. 2018;18(12):1680-1687. doi: 10.2174/1871520618666180830110700. Anticancer Agents Med Chem. 2018. PMID: 30160218

9

PDK2 induces cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3.

Hu T, Yu S, Li Y, Ren H, Ning Q, Wang J, Liang X, Li M. Hu T, et al. Among authors: yu s. J Drug Target. 2019 Apr;27(4):460-465. doi: 10.1080/1061186X.2018.1550648. Epub 2018 Dec 4. J Drug Target. 2019. PMID: 30457021

10

HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin- Resistance in Lung Adenocarcinoma Cells.

Yu S, Ren H, Li Y, Liang X, Ning Q, Chen X, Chen M, Hu T. Yu S, et al. Anticancer Agents Med Chem. 2018;18(14):2062-2067. doi: 10.2174/1871520619666181203110835. Anticancer Agents Med Chem. 2018. PMID: 30501603

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25,750 results

Search Page

Filters